The role of mitochondrial DNA copy number in neuropsychiatric disorders: A bidirectional two-sample Mendelian randomization study.

(1,2) Mengqi Niu, (1,2) Chen Chen, (1-10) Michael Maes

1. Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China

2. Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences, Chengdu, 610072, China

3. Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

4. Program in Mental Health, Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

5. Cognitive Impairment and Dementia Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

6. Cognitive Fitness and Biopsychological Technology Research Unit, Faculty of Medicine Chulalongkorn University, Bangkok, 10330, Thailand, Bangkok, 10330, Thailand

7. Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria

8. Research Institute, Medical University of Plovdiv, Plovdiv, Bulgaria

9. Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea

Corresponding author:

Prof. Dr. Michael Maes, M.D., Ph.D.

Sichuan Provincial Center for Mental Health

Sichuan Provincial People's Hospital,

School of Medicine,

University of Electronic Science and Technology of China

Chengdu 610072

China

Email: 770552576@qq.com

# **Michael Maes Google Scholar profile**

 $\label{eq:NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Prof. Dr. Michael Maes, M.D., Ph.D.$ 

https://scholar.google.co.th/citations?user=1wzMZ7UAAAAJ&hl=th&oi=ao

Highly cited author: 2003-2023 (ISI, Clarivate)

ScholarGPS: Worldwide #1 in molecular neuroscience; #1/4 in pathophysiology

Expert worldwide medical expertise ranking, Expertscape (December 2022), worldwide:

#1 in CFS, #1 in oxidative stress, #1 in encephalomyelitis, #1 in nitrosative stress, #1 in nitrosation,

#1 in tryptophan, #1 in aromatic amino acids, #1 in stress (physiological), #1 in neuroimmune;

#2 in bacterial translocation; #3 in inflammation, #4-5: in depression, fatigue and psychiatry.

# Abstract

Background. Inconsistent findings characterize studies on mitochondrial DNA copy number (mtDNA-CN) and its relation to neuropsychiatric disorders. This bidirectional two-sample Mendelian Randomization (MR) study explores potential causal links between mtDNA-CN and neuropsychiatric disorders, including Alzheimer's disease, Attention-deficit/hyperactivity disorder, Anorexia nervosa, Autism spectrum disorder (ASD), Bipolar disorder, Major depressive disorder, Obsessive-compulsive disorder, Schizophrenia, Anxiety disorders, and Post-traumatic stress disorder.

Methods. Genetic associations with mtDNA-CN were drawn from the UK Biobank's GWAS data (n = 395,718), while neuropsychiatric disorder data came from the Psychiatric Genomics Consortium and FinnGen Consortium. Three MR methods—Inverse Variance Weighting (IVW), MR-Egger, and Weighted Median—were used to establish relationships. Cochran's Q test, MR-PRESSO, and MR-Egger's intercept test assessed heterogeneity and pleiotropy. A leave-one-out analysis evaluated the impact of individual SNPs on MR results, and a bidirectional analysis examined the relationship between mtDNA-CN and neuropsychiatric disorders.

Results. The MR analysis indicated a causal relationship between mtDNA-CN and ASD using the IVW method (OR = 0.735, 95%CI: 0.597 to 0.905; P = 0.004). Conversely, a causal relationship was identified between Anxiety disorders and mtDNA-CN ( $\beta$ = 0.029, 95%CI: 0.010 to 0.048; P = 0.003). No causal associations were found for other disorders. Sensitivity tests corroborated the robustness of these findings.

Conclusion. In this study, potential causal relationships between mtDNA-CN and both ASD and Anxiety disorders were established. These findings provide insights into the biological mechanisms of mtDNA-CN on ASD and underscore the significance of mtDNA copy number as a potential biomarker for Anxiety disorders.

Keywords: mitochondrial DNA copy number, neuropsychiatric disorders, bidirectional, two-sample Mendelian randomization study.

1.Introduction

Mitochondria are critical organelles regulating cellular energy production, metabolism, proliferation, and apoptosis (1). They possess their own genome known as mitochondrial DNA (mtDNA), which is a circular, intron-free, double-stranded, haploid molecule approximately 16.6 kb in size. This genome encodes several proteins essential for cellular energy metabolism (2). The number of mtDNA copies, which represents the quantity of mtDNA molecules in a single cell, is an important indicator of mitochondrial function and the cellular metabolic state (3). Recent studies have linked variations in mtDNA copy number (mtDNA-CN) to a variety of human diseases, including metabolic syndrome, cardiovascular diseases, neurodegenerative diseases, and cancer (4-6).

Mental disorders rank second in terms of premature mortality and disability, constituting one of the most significant public health challenges on a global scale. They are frequently linked to cognitive, emotional, or behavioral alterations. Mental disorders are believed to arise from intricate interplays between genetic predisposition and environmental factors (7, 8). Existing studies have shown that mtDNA-CN alterations are associated with Alzheimer's disease (AD) (9, 10), attention-deficit/hyperactivity disorder (ADHD) (11-13), autism spectrum disorder (ASD) (14-17), bipolar disorder (BD) (18-21), major depressive disorder (MDD) (18, 22-27), schizophrenia (SCZ) (28-32), anxiety disorders (33, 34) and post-traumatic stress disorder (PTSD) (35-37), therefore, may be related to the occurrence and development of neuropsychiatric disorders. However, the observational results of different studies are controversial. To date, it is not clear whether there is a causal relationship between mtDNA-CN and these neuropsychiatric disorders. In addition, whether there is reverse causality for neuropsychiatric disorders affecting mtDNA-CN remains to be investigated.

The relationship between exposure and outcomes in traditional observational epidemiology is influenced by various factors, such as confounding elements and reverse causation. Moreover, this approach has limitations due to its time-consuming nature and high demands on resources (38). The recently developed Mendelian randomization (MR) design has been employed to investigate whether specific exposures have a causal effect on particular outcomes (39). MR methods use genetic variants such as single nucleotide polymorphisms (SNPs) as instrumental variables for exposures (40). By leveraging the random assortment of alleles during meiosis and the fixed allocation at conception, MR studies are less susceptible to confounding factors and reverse causality biases. Moreover, using summary statistics from genome-wide association studies (GWAS) in a two-sample MR approach significantly enhances the statistical power to infer causality (41). To date, no studies have utilized the MR design to investigate the association between mtDNA-CN and neuropsychiatric disorders, nor have any studies explored the reverse relationship using this method.

In this study, based on data from large-sample GWAS, we conducted a bidirectional two-sample MR analysis to investigate the association between mtDNA-CN and ten common neuropsychiatric disorders: AD, ADHD, anorexia nervosa (AN), ASD, BD, MDD, obsessive-compulsive disorder (OCD), SCZ, anxiety disorders, and PTSD.

#### 2.Methods:

## 2.1. Overall Study Design

We conducted a bidirectional two-sample MR analysis using the latest summary statistics from GWAS to explore the relationship between mtDNA-CN and neuropsychiatric disorders and to assess whether these neuropsychiatric disorders could lead to changes in mtDNA-CN. Our MR analysis adhered to three critical assumptions: (1) The selected SNPs are associated with the exposure; (2) The SNPS are independent of confounders of the exposure-outcome relationship (independence assumption); (3) The SNPS affect the outcome only through exposure (42). The study design included outcomes for 10 neuropsychiatric disorders: AD, ADHD, AN, ASD, BD, MDD, OCD, SCZ, anxiety disorders, and PTSD. Figure 1 illustrates the study workflow.

## 2.2. Data Sources

Table 1 presents the GWAS meta-analysis information regarding mtDNA-CN, involving 395,718 participants from the UK Biobank of European ancestries. It used a novel approach called "AutoMitoC" developed by Chong et al. (43) to identify novel common and rare genetic determinants of mtDNA-CN. This represents the most extensive genetic evaluation published to date.

Information about neuropsychiatric disorders related to GWAS summary statistics are shown in **Table 1** and sourced from the Psychiatric Genomics Consortium (PGC: https://www.med.unc.edu/pgc/). Sample sizes are detailed as follows: AD (71,880 cases and 383,378 controls) (44), ADHD (20,183 cases and 35,191 controls) (45), AN (3,495 cases and 10,982 controls) (46), ASD (18,381 cases and 27,969 controls) (47), BD (41,917 cases and 371,549 controls) (48), MDD (59,851 cases and 113,154 controls) (49), OCD (2,688 cases and 7,037 controls) (50), SCZ (52,017 cases and 75,889 controls) (51). Summary statistics for anxiety disorders (44,663 cases and 301,879 controls) and PTSD (2,615 cases and 368,054 controls) were published in 2023 by the FinnGen Consortium (https://r10.finngen.fi/). The study exclusively used European population data to minimize population stratification biases.

## 2.3. Selection of Instrumental Variables

Strict criteria were employed to select suitable instrumental variables. (1) All SNPs achieving genome-wide significance ( $P < 5 \times 10^{-8}$ ) were included. When the number of suitable instrumental variables was restricted to 10 or fewer, the p-value threshold was relaxed to  $1 \times 10^{-6}$  (52). (2) To ensure the independence of the instruments used for exposure, SNPs in linkage disequilibrium (LD) ( $r^2 < 0.001$  within a 10,000 kb window) were excluded (52). (3) Palindromic SNPs with a medium allele frequency (MAF) were removed (53). (4) The LDtrait Tool (https://ldlink.nih.gov) (54) was used to assess potential confounders including alcohol consumption, smoking behavior, socioeconomic status, and education (55). (5) In addition, the proportion of variance explained (PVE) by SNPS was assessed using the following formula:  $PVE = 2 \times MAF \times (1 - MAF) \times beta^2$  (56), and the F-statistic was calculated to determine the strength of the SNP using the following formula:  $F = PVE \times (N - 2)/(1 - PVE)$  (56). In cases where MAF data were not provided in the original study, an alternative formula was used:  $F = beta^2/se^2$  (57). The statistical power of F > 10 indicates a strong correlation (58).

# 2.4. Statistical Analysis

Three MR methods were used to investigate the causal relationship between mtDNA-CN and neuropsychiatric disorders: Inverse Variance Weighted (IVW), MR-Egger, and Weighted Median (WM). The Cochran's Q test within the IVW method was used to detect heterogeneity among SNPs, with a significance level set at P < 0.05. The MR-PRESSO analysis identified and corrected for potential pleiotropic outliers, and the intercept P-value in the MR-Egger analysis evaluated horizontal pleiotropy, with significance considered at P < 0.05 (59). The leave-one-out method was implemented to determine whether the estimates were driven by any single SNP (55).

To ensure the reliability of the final analysis results, the following screening criteria were used as filters to identify robust significant causality: (1) IVW method is considered the primary approach for determining the association between exposures and outcomes. MR-Egger and WM methods reinforce the IVW results by analyzing the link between mtDNA-CN and neuropsychiatric disorders from multiple perspectives. (2) The direction of the MR analysis results (beta values) is consistent across all three methods. (3) Given our reliance on the IVW method, we adjust all P values derived from IVW using the False Discovery Rate (FDR) correction. The adjusted results are denoted as P\*. A statistical significance threshold is set at 0.05. A P value  $\leq 0.05$  with P\*  $\leq 0.05$  indicates a significant causal relationship, whereas a P value  $\leq 0.05$  with P\* > 0.05 suggests evidence of a potential causal relationship.

Statistical analyses were performed using the statistical software R (version 4.3.2) with packages including

MendelianRandomization, MR-PRESSO, and TwoSampleMR. For binary outcomes, odds ratios (OR) and their 95% confidence intervals (CI) quantified the strength of the causal relationships. For continuous outcomes, results were reported as beta and standard error (SE) along with their respective 95% CIs.

## 2.5. Ethical Approval and Consent to Participate

This study was reported according to the Strengthening the Reporting of Observational Studies in Epidemiology Using MR (STROBE-MR) checklist (60). Our analyses were based on publicly available data that had been approved by relevant review boards. Therefore, no additional ethical approval is required.

## 3.Results:

3.1. Genetic prediction of the relationship between mtDNA-CN and neuropsychiatric disorders

## 3.1.1. Selection of Instrumental Variables

To ensure precision in our analysis, the initial pool of 11,173,383 SNPs related to mtDNA-CN was reduced following criteria for significance ( $P < 5 \times 10^{-8}$ ) and LD ( $r^2 < 0.001$  within a 10,000 kb window). This refinement process left 67 SNPs eligible for the main analysis, as detailed in **Additional file 1: Table S1**.

For AD, 64 of these SNPs were successfully extracted. After removing palindromic sequences with MAF, 55 SNPs remained. These had an F-statistic 88.18 (range of 32.25 to 461.23). In ADHD, from the original 67 SNPs, 58 were extracted and 51 remained after the same exclusion criteria, showing an F-statistic 86.69 (range from 32.25 to 461.22). Similar analysis in AN and ASD resulted in 63 initial SNPs, with 56 remaining post-exclusion, and F-statistics 86.76 (from 32.25 to 461.22). For BD, we started with 60 SNPs and retained 53, with F-statistics 89.43 (ranging from 32.25 to 461.22). This pattern was mirrored in MDD and OCD where from initial figures of 61 and 60 SNPs, 53 were retained in each case, both with an F-statistic 88.46 (range of 32.25 to 461.22). SCZ saw 60 initial SNPs with 53 remaining, exhibiting an F-statistic 89.43 (range of 32.25 to 461.22). For Anxiety Disorders and PTSD, 61 SNPs were identified, and 53 remained after exclusions, with an F-statistic 86.08 (ranging from 32.25 to 461.23). Additionally, no significant associations with confounding factors such as alcohol consumption, smoking, socioeconomic status, and education were found when these SNPs were assessed using the LDtrait Tool (https://ldlink.nih.gov). Detailed information on the SNPs finally used as instrumental variables to explore the relationship between mtDNA-CN and neuropsychiatric disorders is available in **Additional file 1: Tables S2-S11**.

As shown in **Table 2**, the primary IVW analysis indicated a statistically significant causal relationship between mtDNA-CN and ASD (OR = 0.735, 95%CI: 0.597 to 0.905; P = 0.004). The secondary analysis methods WM also showed statistical significance (OR = 0.735, 95%CI: 0.550 to 0.982; P = 0.037). However, no evidence was found for a causal relationship between mtDNA-CN and AD, ADHD, AN, BD, MDD, OCD, SCZ, Anxiety Disorders, or PTSD across all three MR analysis methods (IVW, MR-Egger, WM). Sensitivity analyses with the MR-PRESSO method detected horizontal pleiotropic outliers only in AD, with no outliers found for other disorders. After excluding the outlier SNP, the MR-Egger intercept of all neuropsychiatric disorders showed no evidence of horizontal pleiotropy (P > 0.05). The Cochran's Q test for heterogeneity identified significant heterogeneity only among SNPs for BD, MDD, and SCZ; no significant heterogeneity was observed for other disorders. The leave-one-out method confirmed that the causal relationships were not driven by any individual SNP. Scatter plots of the forward analysis and the leave-one-out analysis graphs for each SNP-neuropsychiatric disorder association are summarized in **Figure 2** and **Additional file 1: Figure S1**, respectively.

In our analysis examining the causal relationship between mtDNA-CN and ASD, the directionality (beta values) of the MR results were consistent across three different methodologies. Furthermore, upon adjusting the P-values from the IVW method using the FDR, the adjusted P-value (P\*) was 0.038. This suggests a statistically significant causal association between mtDNA-CN and ASD.

#### 3.2. Genetic prediction of the relationship between neuropsychiatric disorders and mtDNA-CN

## 3.2.1 Selection of Instrumental Variables

In our reverse causality analysis of the relationship between neuropsychiatric disorders and mtDNA-CN, SNPs were rigorously selected based on statistical significance ( $P < 5 \times 10^{-8}$ ) and LD ( $r^2 < 0.001$  within a 10,000 kb window). This selection resulted in the retention of 30 SNPs for AD, 12 for ADHD, 52 for BD, and 158 for SCZ. After this filtering, 29 SNPs for AD were extracted from the SNPs of mtDNA-CN and further reduced to 23 post-exclusion of palindromic sequences with MAF, yielding F-statistics 93.03 (ranging from 30.29 to 670.46). For ADHD, of the 12 extracted SNPs, 11 remained after similar exclusions, with F-statistics 34.11 (ranging from 30.57 to 52.71). In BD, 51 SNPs were initially extracted, and 44 remained, showing F-statistics 38.11 (range from 30.08 to 79.65). For SCZ, 158 SNPs were extracted, and 130 remained post-exclusion, with F-statistics 45.35 (ranging from 29.46 to 175.27).

For AN, ASD, MDD, OCD, anxiety disorders, and PTSD, where the number of suitable instrumental variables was fewer than 10, the IV selection p-value threshold was relaxed to  $1 \times 10^{-6}$ . This included 5 SNPs for AN, 16 for

ASD, 22 for MDD, 2 for OCD, 50 for anxiety disorders, and 2 for PTSD. After this filtering, 4 SNPs for AN were extracted from the SNPs of mtDNA-CN and further reduced to 4 post-exclusion of palindromic sequences with MAF, yielding F-statistics 28.02 (ranging from 24.11 to 34.41). For ASD, of the 15 extracted SNPs, 14 remained after similar exclusions, with F-statistics 26.59 (ranging from 24.07 to 35.77). In MDD, 22 SNPs were initially extracted, and 17 remained, showing F-statistics 28.54 (range from 24.57 to 43.66). For OCD, 2 SNPs were extracted, and 2 remained post-exclusion, with F-statistics 25.09 (ranging from 24.62 to 25.57). In anxiety disorders, 50 SNPs were initially extracted, and 41 remained, showing F-statistics 28.26 (range from 24.01 to 46.75). For PTSD, 2 SNPs were extracted, and 2 remained post-exclusion, with F-statistics 27.58 (ranging from 27.49 to 27.66). Additionally, no significant associations with confounding factors such as alcohol consumption, smoking, socioeconomic status, and education were found when these SNPs were assessed using the LDtrait Tool (https://ldlink.nih.gov). Detailed information on the genetic variants (SNPs) finally used as instrumental variables for the reverse relationship between neuropsychiatric disorders and mtDNA-CN is available in Additional file 1: Table S12-21.

## 3.2.2 MR Analysis Results

As shown in **Table 3**, the primary IVW analysis revealed a statistically significant causal relationship between anxiety disorders and mtDNA-CN ( $\beta$  = 0.029, 95%CI: 0.010 to 0.048; P = 0.003). However, no evidence of a causal relationship was found between mtDNA-CN and AD, ADHD, AN, ASD, BD, MDD, OCD, SCZ, or PTSD across all three MR analysis methods (IVW, MR-Egger, WM). Sensitivity analyses with the MR-PRESSO method detected one horizontal pleiotropic outlier in AD, BD, SCZ, and two in anxiety disorders, with no outliers observed for other disorders. After excluding these outliers, the MR-Egger intercept of all outcomes showed no evidence of horizontal pleiotropy (P > 0.05). The Cochran's Q test for heterogeneity identified significant heterogeneity only among SNPs for AD, BD, MDD, and SCZ; no significant heterogeneity was observed for other disorders. Meanwhile, the "leave one" method confirms that a single SNP does not affect causal relationships. The reverse analysis scatter plots and the leave-one-out analysis graphs for each SNP of neuropsychiatric disorder association with mtDNA-CN are summarized in **Figure 3** and **Additional file 1: Figure S2**, respectively. For OCD and PTSD, only 2 SNPs were available for analysis, which was insufficient for comprehensive MR-Egger, WM, MR-PRESSO methods, and leave-one-out analysis.

In examining the statistically significant causal relationship between anxiety disorders and mtDNA-CN, the directional consistency (beta values) of the MR results was observed across three different methodologies.

Furthermore, after adjusting the P-values obtained from the IVW method using the FDR, the adjusted P-value (P\*) was 0.030. This indicates a significant causal association between anxiety disorders and mtDNA-CN.

## 4. Discussion

Leveraging a vast array of publicly available genetic data, our study explored the causal relationships between mtDNA-CN and neuropsychiatric disorders. To our knowledge, this is the first comprehensive study to utilize bidirectional two-sample MR to investigate the association between mtDNA-CN and various neuropsychiatric disorders from a genetic predictive perspective. We found significant causal effects of mtDNA-CN on ASD and of anxiety disorders on mtDNA-CN. No other forward or reverse causal relationships were identified between mtDNA-CN and other neuropsychiatric disorders (including AD, ADHD, AN, BD, MDD, OCD, SCZ, PTSD).

This MR study revealed that a decrease in mtDNA-CN could increase the likelihood of developing ASD. Two observational studies observed a reduction in mtDNA-CN in peripheral blood mononuclear cells and leukocytes among patients with ASD, consistent with our findings (14, 15). A reduction in mtDNA-CN implies a lower DNA copy number per mitochondrion, potentially leading to diminished ATP synthesis capacity, thereby compromising the energy supply to neuronal cells, affecting their normal function and development, particularly during early brain development stages (61-63). According to a recent gene network analysis that examined mRNA expression in the brains of children with ASD, it was found that ASD is associated with mitochondrial dysfunctions, specifically in the electron transport chain and ATP production (64). Insufficient energy supply may also trigger programmed cell death (apoptosis), especially in neuronal cells, impacting the structural and functional development of the brain and further relating to autism symptoms (61, 63). Mitochondrial dysfunction may affect the synthesis and release of neurotransmitters such as glutamate and GABA, key chemicals in regulating mood, cognition, and behavior, potentially linked to the social and communication challenges observed in autism (62, 63). However, Yoo et al. (16) observed an increase in peripheral blood mtDNA-CN in patients with ASD, which was associated with neurological manifestations and communication; similarly, Chen et al. (17) observed a higher relative mtDNA-CN in children with autism compared to healthy controls. These observations do not contradict our findings; in fact, they may reveal the complex regulatory mechanisms of mitochondria in autism. In patients with established autism, certain tissues may exhibit mitochondrial dysfunction due to genetic or environmental factors. To compensate for this energy production shortfall, other tissues (such as blood cells) may increase mtDNA-CN to maintain normal physiological functions (65, 66). Furthermore, patients with autism may exhibit a chronic low-grade inflammatory state, where inflammation can induce mitochondrial biogenesis and mtDNA replication as part of the immune cell

activation and cellular stress response (65-67). Additionally, cells may increase mtDNA-CN in response to stress (such as oxidative stress) to enhance their energy production capacity, aiming to protect cells from further damage (65, 66).

Our study also discovered that the occurrence of anxiety disorders leads to an increase in mtDNA-CN. Previous research supports our findings; Tymofiyeva et al. (33) found that salivary mtDNA-CN was associated with the severity of anxiety symptoms in adolescent samples. In another study, higher levels of blood leukocyte mtDNA-CN were associated with a lifetime history of anxiety disorders (34). Firstly, chronic stress, including induced glucocorticoids, pro-inflammatory cytokines, and oxidative stress activation, may damage mitochondria and stimulate new mitochondrial generation and DNA replication as a compensatory mechanism to maintain energy (65, 66, 68-70). Meanwhile, chronic also stimulates the body's HPA axis output stress (hypothalamic-pituitary-adrenal axis), leading to elevated cortisol levels. Cortisol acts on coordinated physiological systems, inducing metabolic stress and affecting mitochondrial density and function by altering the expression of mitochondrial and nuclear genes that impact mitochondria. Glucocorticoid receptors bind to mitochondrial membranes to regulate membrane potential (71-74). Additionally, anxiety disorders may increase mtDNA-CN by affecting mitochondrial-related cellular signaling pathways, including AMPK (AMP-activated protein kinase) and sirtuins, which are key proteins active during cellular energy crises and stress (75-79).

Our bidirectional MR analysis did not identify any forward or reverse causal relationships between mtDNA-CN and other neuropsychiatric disorders (including AD, ADHD, AN, BD, MDD, OCD, SCZ, PTSD). Previous observational studies have explored the relationships between mtDNA-CN and AD (9, 10), ADHD (11-13), BD (18-21), MDD (18, 22-27), SCZ (28-32), and PTSD (35-37), with limited and highly controversial findings. Similar to our results, a community-based cohort meta-analysis using MR analysis did not reveal a causal relationship between blood mtDNA-CN and cognition (9). Other studies indicated a significant reduction in mtDNA-CN in the brains of AD patients (10). Three observational studies reported elevated mtDNA-CN in ADHD (11-13). A recent meta-analysis found no predictable relationship between BD diagnosis and mtDNA-CN, regardless of BD subtype; however, BD type 1 patients showed a decrease, while BD type 2 patients showed an increase in mtDNA-CN (18). Fries et al. (19) and Rollins et al. (20) found a significant increase in mtDNA-CN among BD patients compared to healthy controls, whereas de Sousa et al. (21) observed no significant difference in mtDNA-CN between BD patients and healthy controls. In a recent longitudinal study by Verhoeven et al. (22), no evidence of an association between depressive symptoms and mtDNA-CN was found in a community-based adult sample of individuals with depression. He et al. (23) also found no relationship between white blood cell

mtDNA-CN and MDD in young people. However, some studies suggest a high level of mtDNA-CN is associated with depression (18, 24-26); in another study, a decrease in mtDNA-CN in adult MDD was observed (27). Li et al. (28) and Shivakumar et al. (29) reported a significant reduction in peripheral blood mtDNA-CN in patients with SCZ; some reported a decrease in mtDNA-CN in the brains of SCZ patients (30, 31); while others reported no differences (32). In Cai et al.'s study, Holocaust survivors with PTSD showed no differences in mtDNA-CN in PTSD patients (36, 37). Our study is the first to use MR analysis to explore the bidirectional causal relationships between mtDNA-CN and other neuropsychiatric disorders (including AD, ADHD, AN, BD, MDD, OCD, SCZ, PTSD) from a genetic prediction standpoint, and our findings did not reveal any associations.

The current study has several strengths. Firstly, it included mtDNA-CN and 10 neuropsychiatric disorders, making it the first comprehensive MR study on the relationship between mtDNA-CN and neuropsychiatric disorders. Secondly, our conclusions are based on genetic instrumental variables and multiple MR analysis methods for causal inference. The results are robust, not confounded by horizontal pleiotropy or other factors. However, our study also has limitations. Firstly, due to the lack of individual information, we could not further stratify the population for analysis. Secondly, the study is based on European databases, therefore our conclusions cannot be extended to other ethnic groups, limiting the generalizability of our results. Future research could include populations with different characteristics (such as race and age) in MR studies may increase the representation of different populations. Lastly, we used more relaxed thresholds to assess results, which may increase some false positives while allowing a more comprehensive assessment of strong associations between mtDNA-CN and neuropsychiatric disorders.

## 5. Conclusion:

In this study, potential causal relationships between mtDNA-CN and both ASD and anxiety disorders were established. Our findings indicate that a reduction in mtDNA-CN can increase the likelihood of developing ASD; the occurrence of anxiety disorders can lead to an increase in mtDNA-CN. These findings provide insights into the biological mechanisms of mtDNA-CN on ASD and underscore the significance of mtDNA-CN as a potential biomarker for anxiety disorders.

# Ethical statement

Our analyses were based on publicly available data that had been approved by relevant review boards. Therefore,

no additional ethical approval is required.

# Funding

There was no specific funding for this specific study.

# Conflict of interest

The authors have no conflicts of interest with any commercial or other association in connection with the submitted article.

# Acknowledgment

We thank the participants and investigators of the UK Biobank, Psychiatric Genomics Consortium and FinnGen Consortium.

# Author's contributions

All the contributing authors have participated in the preparation of the manuscript.

# Data Access Statement.

The datasets used and/or analyzed during the current study are presented in the manuscript. Summary statistics for GWAS are publicly available.

## References:

1. Li Y, Sundquist K, Zhang N, Wang X, Sundquist J, Memon AA. Mitochondrial related genome-wide Mendelian randomization identifies putatively causal genes for multiple cancer types. EBioMedicine. 2023;88:104432.

2. Cai X, Li X, Liang C, Zhang M, Xu Y, Dong Z, et al. Mitochondrial DNA copy number is associated with Crohn's disease: a comprehensive Mendelian randomization analysis. Scientific reports. 2023;13(1):21016.

3. Castellani CA, Longchamps RJ, Sun J, Guallar E, Arking DE. Thinking outside the nucleus: Mitochondrial DNA copy number in health and disease. Mitochondrion. 2020;53:214-23.

4. Huang C, Chen L, Li J, Ma J, Luo J, Lv Q, et al. Mitochondrial DNA Copy Number and Risk of Diabetes Mellitus and Metabolic Syndrome. The Journal of clinical endocrinology and metabolism. 2023;109(1):e406-e17.

5. Liu X, Sun X, Zhang Y, Jiang W, Lai M, Wiggins KL, et al. Association Between Whole Blood-Derived Mitochondrial DNA Copy Number, Low-Density Lipoprotein Cholesterol, and Cardiovascular Disease Risk. Journal of the American Heart Association. 2023;12(20):e029090.

6. Filograna R, Mennuni M, Alsina D, Larsson NG. Mitochondrial DNA copy number in human disease: the more the better? FEBS letters. 2021;595(8):976-1002.

7. Charlson F, van Ommeren M, Flaxman A, Cornett J, Whiteford H, Saxena S. New WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis. Lancet (London, England). 2019;394(10194):240-8.

8. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). 2018;392(10159):1789-858.

9. Zhang Y, Liu X, Wiggins KL, Kurniansyah N, Guo X, Rodrigue AL, et al. Association of Mitochondrial DNA Copy Number With Brain MRI Markers and Cognitive Function: A Meta-analysis of Community-Based Cohorts. Neurology. 2023;100(18):e1930-e43.

10. Klein HU, Trumpff C, Yang HS, Lee AJ, Picard M, Bennett DA, et al. Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer's disease brain. Molecular neurodegeneration. 2021;16(1):75.

11. Kim JI, Lee SY, Park M, Kim SY, Kim JW, Kim SA, et al. Peripheral Mitochondrial DNA Copy Number is Increased in Korean Attention-Deficit Hyperactivity Disorder Patients. Frontiers in psychiatry. 2019;10:506.

12. Öğütlü H, Esin İ S, Erdem HB, Tatar A, Dursun OB. Mitochondrial DNA Copy Number is Associated with Attention Deficit Hyperactivity Disorder. Psychiatria Danubina. 2020;32(2):168-75.

13. Öğütlü H, Esin İ S, Erdem HB, Tatar A, Dursun OB. Mitochondrial DNA copy number may be associated with attention deficit/hyperactivity disorder severity in treatment: a one-year follow-up study. International journal of psychiatry in clinical practice. 2021;25(1):37-42.

14. Singh K, Singh IN, Diggins E, Connors SL, Karim MA, Lee D, et al. Developmental regression and mitochondrial function in children with autism. Annals of clinical and translational neurology. 2020;7(5):683-94.

15. Valiente-Pallejà A, Torrell H, Muntané G, Cortés MJ, Martínez-Leal R, Abasolo N, et al. Genetic and clinical evidence of mitochondrial dysfunction in autism spectrum disorder and intellectual disability. Human molecular genetics. 2018;27(5):891-900.

16. Yoo HJ, Park M, Kim SA. Difference in mitochondrial DNA copy number in peripheral blood cells between probands with autism spectrum disorders and their unaffected siblings. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2017;18(2):151-6.

17. Chen S, Li Z, He Y, Zhang F, Li H, Liao Y, et al. Elevated mitochondrial DNA copy number in peripheral blood cells is associated with childhood autism. BMC psychiatry. 2015;15:50.

18. Calarco CA, Keppetipola SM, Kumar G, Shipper AG, Lobo MK. Whole blood mitochondrial copy number in clinical populations with mood disorders: A meta-analysis: Blood mitochondrial copy number and mood disorders. Psychiatry research. 2024;331:115662.

19. Fries GR, Bauer IE, Scaini G, Wu MJ, Kazimi IF, Valvassori SS, et al. Accelerated epigenetic aging and mitochondrial DNA copy number in bipolar disorder. Translational psychiatry. 2017;7(12):1283.

20. Rollins BL, Morgan L, Hjelm BE, Sequeira A, Schatzberg AF, Barchas JD, et al. Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence. Molecular neuropsychiatry. 2018;3(3):157-69.

21. de Sousa RT, Uno M, Zanetti MV, Shinjo SM, Busatto GF, Gattaz WF, et al. Leukocyte mitochondrial DNA copy number in bipolar disorder. Progress in neuro-psychopharmacology & biological psychiatry. 2014;48:32-5.

22. Verhoeven J, Révész D, Picard M, Epel E, Wolkowitz O, Matthews K, et al. Depression, telomeres and mitochondrial DNA: between-and within-person associations from a 10-year longitudinal study. Molecular psychiatry. 2018;23(4):850-7.

23. He Y, Tang J, Li Z, Li H, Liao Y, Tang Y, et al. Leukocyte mitochondrial DNA copy number in blood is not associated with major depressive disorder in young adults. PloS one. 2014;9(5):e96869.

24. Wang X, Sundquist K, Rastkhani H, Palmér K, Memon AA, Sundquist J. Association of mitochondrial DNA in peripheral blood with depression, anxiety and stress-and adjustment disorders in primary health care patients. European Neuropsychopharmacology. 2017;27(8):751-8.

25. Cai N, Chang S, Li Y, Li Q, Hu J, Liang J, et al. Molecular signatures of major depression. Current Biology. 2015;25(9):1146-56.

26. Edwards AC, Aggen SH, Cai N, Bigdeli TB, Peterson RE, Docherty AR, et al. Chronicity of depression and molecular markers in a large sample of Han Chinese women. Depression and anxiety. 2016;33(11):1048-54.

27. Chang C-C, Jou S-H, Lin T-T, Lai T-J, Liu C-S. Mitochondria DNA change and oxidative damage in clinically stable patients with major depressive disorder. PloS one. 2015;10(5):e0125855.

28. Li Z, Hu M, Zong X, He Y, Wang D, Dai L, et al. Association of telomere length and mitochondrial DNA copy number with risperidone treatment response in first-episode antipsychotic-naïve schizophrenia. Scientific reports. 2015;5(1):18553.

29. Shivakumar V, Rajasekaran A, Subbanna M, Kalmady SV, Venugopal D, Agrawal R, et al. Leukocyte mitochondrial DNA copy number in schizophrenia. Asian journal of psychiatry. 2020;53:102193.

30. Roberts R, Barksdale K, Roche J, Lahti A. Decreased synaptic and mitochondrial density in the postmortem anterior cingulate cortex in schizophrenia. Schizophrenia research. 2015;168(1-2):543-53.

31. Somerville SM, Conley RR, Roberts RC. Mitochondria in the striatum of subjects with schizophrenia. The World Journal of Biological Psychiatry. 2011;12(1):48-56.

32. Torrell H, Montaña E, Abasolo N, Roig B, Gaviria AM, Vilella E, et al. Mitochondrial DNA (mtDNA) in brain samples from patients with major psychiatric disorders: gene expression profiles, mtDNA content and presence of the mtDNA common deletion. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2013;162(2):213-23.

33. Tymofiyeva O, Henje Blom E, Ho TC, Connolly CG, Lindqvist D, Wolkowitz OM, et al. High levels of mitochondrial DNA are associated with adolescent brain structural hypoconnectivity and increased anxiety but not depression. Journal of affective disorders. 2018;232:283-90.

34. Tyrka AR, Parade SH, Price LH, Kao H-T, Porton B, Philip NS, et al. Alterations of Mitochondrial DNA Copy Number and Telomere Length With Early Adversity and Psychopathology. Biological psychiatry. 2016;79(2):78-86.

35. Cai N, Fňašková M, Konečná K, Fojtová M, Fajkus J, Coomber E, et al. No Evidence of Persistence or Inheritance of Mitochondrial DNA Copy Number in Holocaust Survivors and Their Descendants. Frontiers in genetics. 2020;11:87.

36. Bersani FS, Morley C, Lindqvist D, Epel ES, Picard M, Yehuda R, et al. Mitochondrial DNA copy number is reduced in male combat veterans with PTSD. Progress in neuro-psychopharmacology & biological psychiatry. 2016;64:10-7.

37. Brunst KJ, Sanchez Guerra M, Gennings C, Hacker M, Jara C, Bosquet Enlow M, et al. Maternal Lifetime Stress and Prenatal Psychological Functioning and Decreased Placental Mitochondrial DNA Copy Number in the PRISM Study. American journal of epidemiology. 2017;186(11):1227-36.

38. Kroeger PT, Jr., Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. Current opinion in obstetrics & gynecology. 2017;29(1):26-34.

39. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? International journal of epidemiology. 2003;32(1):1-22.

40. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genetic epidemiology. 2013;37(7):658-65.

41. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. American journal of epidemiology. 2013;178(7):1177-84.

42. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Statistics in medicine. 2008;27(8):1133-63.

43. Chong M, Mohammadi-Shemirani P, Perrot N, Nelson W, Morton R, Narula S, et al. GWAS and ExWAS of blood mitochondrial DNA copy number identifies 71 loci and highlights a potential causal role in dementia. eLife. 2022;11.

44. Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. Nature genetics. 2019;51(3):404-13.

45. Martin J, Walters RK, Demontis D, Mattheisen M, Lee SH, Robinson E, et al. A Genetic Investigation of Sex Bias in the Prevalence of Attention-Deficit/Hyperactivity Disorder. Biological psychiatry. 2018;83(12):1044-53.

46. Duncan L, Yilmaz Z, Gaspar H, Walters R, Goldstein J, Anttila V, et al. Significant Locus and Metabolic Genetic Correlations Revealed in Genome-Wide Association Study of Anorexia Nervosa. The American journal of psychiatry. 2017;174(9):850-8.

47. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk variants for autism spectrum disorder. Nature genetics. 2019;51(3):431-44.

48. Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature genetics. 2021;53(6):817-29.

49. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nature genetics. 2018;50(5):668-81.

50. Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. Molecular psychiatry. 2018;23(5):1181-8.

51. Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022;604(7906):502-8.

52. Sun W, Wu X, Yang H, Yuan S, Chen J, Fang Y, et al. Identifying causal associations between women's reproductive traits and risk of schizophrenia: a multivariate validated two-sample Mendelian randomization analysis. BMC psychiatry. 2024;24(1):161.

53. Li YS, Xia YG, Liu YL, Jiang WR, Qiu HN, Wu F, et al. Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study. PloS one. 2024;19(2):e0297883.

54. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics (Oxford, England). 2015;31(21):3555-7.

55. Jiang M, Yan W, Zhang Y, Lu Z, Lu T, Zhang D, et al. Phosphodiesterase and psychiatric disorders: a two-sample Mendelian randomization study. Journal of translational medicine. 2023;21(1):560.

56. Papadimitriou N, Dimou N, Tsilidis KK, Banbury B, Martin RM, Lewis SJ, et al. Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nature communications. 2020;11(1):597.

57. Xie J, Huang H, Liu Z, Li Y, Yu C, Xu L, et al. The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study. Hepatology (Baltimore, Md). 2023;77(3):949-64.

58. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ (Clinical research ed). 2018;362:k601.

59. Liu L, Xue Y, Chen Y, Chen T, Zhong J, Shao X, et al. Acne and risk of mental disorders: A two-sample Mendelian randomization study based on large genome-wide association data. Frontiers in public health. 2023;11:1156522.

60. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ (Clinical research ed). 2021;375:n2233.

61. Zhang Z, Yang D, Zhou B, Luan Y, Yao Q, Liu Y, et al. Decrease of MtDNA copy number affects mitochondrial function and involves in the pathological consequences of ischaemic stroke. Journal of cellular and molecular medicine. 2022;26(15):4157-68.

62. Otten ABC, Kamps R, Lindsey P, Gerards M, Pendeville-Samain H, Muller M, et al. Tfam Knockdown Results in Reduction of mtDNA Copy Number, OXPHOS Deficiency and Abnormalities in Zebrafish Embryos. Frontiers in cell and developmental biology. 2020;8:381.

63. Balachandar V, Rajagopalan K, Jayaramayya K, Jeevanandam M, Iyer M. Mitochondrial dysfunction: A hidden trigger of autism? Genes & diseases. 2021;8(5):629-39.

64. Gevezova M, Sbirkov Y, Sarafian V, Plaimas K, Suratanee A, Maes M. Autistic spectrum disorder (ASD) - Gene, molecular and pathway signatures linking systemic inflammation, mitochondrial dysfunction, transsynaptic signalling, and neurodevelopment. Brain, behavior, & immunity - health. 2023;30:100646.

65. Lee HC, Yin PH, Lu CY, Chi CW, Wei YH. Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells. The Biochemical journal. 2000;348 Pt 2(Pt 2):425-32.

66. Lee HC, Wei YH. Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. The international journal of biochemistry & cell biology. 2005;37(4):822-34.

67. Rossignol DA, Frye RE. Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism. Frontiers in physiology. 2014;5:150.

68. Maes M, Rachayon M, Jirakran K, Sodsai P, Klinchanhom S, Debnath M, et al. Adverse Childhood Experiences Predict the Phenome of Affective Disorders and These Effects Are Mediated by Staging, Neuroimmunotoxic and Growth Factor Profiles. Cells. 2022;11(9).

69. Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Progress in neuro-psychopharmacology & biological psychiatry. 2011;35(3):676-92.

70. Liesa M, Shirihai Orian S. Mitochondrial Dynamics in the Regulation of Nutrient Utilization and Energy Expenditure. Cell Metabolism. 2013;17(4):491-506.

71. Picard M, Juster RP, McEwen BS. Mitochondrial allostatic load puts the 'gluc' back in glucocorticoids. Nature reviews Endocrinology. 2014;10(5):303-10.

72. Zhang L, Zhou R, Li X, Ursano RJ, Li H. Stress-induced change of mitochondria membrane potential regulated by genomic and non-genomic GR signaling: a possible mechanism for hippocampus atrophy in PTSD. Medical hypotheses. 2006;66(6):1205-8.

73. Atlante A, Calissano P, Bobba A, Giannattasio S, Marra E, Passarella S. Glutamate neurotoxicity, oxidative stress and mitochondria. FEBS letters. 2001;497(1):1-5.

74. Toya S, Takatsuru Y, Kokubo M, Amano I, Shimokawa N, Koibuchi N. Early-life-stress affects the homeostasis of glutamatergic synapses. The European journal of neuroscience. 2014;40(11):3627-34.

75. Zhao AR, Li J, Wang SQ, Bian LH, Li WJ, Guo JY. Stress can affect mitochondrial energy metabolism and AMPK/SIRT1 signaling pathway in rats. Brain research bulletin. 2023;203:110770.

76. Ke R, Xu Q, Li C, Luo L, Huang D. Mechanisms of AMPK in the maintenance of ATP balance during energy metabolism. Cell Biology International. 2018;42(4):384-92.

77. Braidy N, Berg J, Clement J, Khorshidi F, Poljak A, Jayasena T, et al. Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes. Antioxidants & Redox Signaling. 2018;30(2):251-94.

78. Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA, et al. Glucose Restriction Inhibits Skeletal Myoblast Differentiation by Activating SIRT1 through AMPK-Mediated Regulation of Nampt. Developmental Cell. 2008;14(5):661-73.

79. Kang C, Ji LL. Role of PGC-1 $\alpha$  signaling in skeletal muscle health and disease. Annals of the New York Academy of Sciences. 2012;1271(1):110-7.

# Figures

Figure 1 The flowchart of bidirectional Mendelian randomization study explores the causal relationship between mitochondrial DNA copy number and neuropsychiatric disorders. AD: Alzheimer's disease; ADHD: Attention-deficit/hyperactivity disorder; AN: Anorexia nervosa; ASD: Autism spectrum disorder; BD: Bipolar disorder; MDD: Major depressive disorder; OCD: Obsessive compulsive disorder; SCZ: Schizophrenia; PTSD: Post-traumatic stress disorder.

Figure 2 The forward MR analyses: Scatter plots of the association between mtDNA copy number and neuropsychiatric disorders. A Alzheimer's disease, B attention-deficit/hyperactivity disorder, C anorexia nervosa, D autism spectrum disorder, E bipolar disorder, F major depressive disorder, G obsessive compulsive disorder, H Schizophrenia, I anxiety disorders, J post-traumatic stress disorder. Lines in blue, red, and green represent IVW, MR-Egger, and weighted median methods. IVW inverse variance weighting, mtDNA-CN mtDNA copy number, SNP single nucleotide polymorphism.

Figure 3 The reverse MR analyses: Scatter plots of the association between neuropsychiatric disorders and mtDNA copy number . A Alzheimer's disease, B attention-deficit/hyperactivity disorder, C anorexia nervosa, D autism spectrum disorder, E bipolar disorder, F major depressive disorder, G obsessive compulsive disorder, H Schizophrenia, I anxiety disorders, J post-traumatic stress disorder. Lines in blue, red, and green represent IVW, MR-Egger, and weighted median methods. IVW inverse variance weighting, mtDNA-CN mtDNA copy number, SNP single nucleotide polymorphism.

Phenotypes	Study/consortiu	Cases/ controls	Ancestry	PubMed ID/Website
	m			
Mitochondrial DNA copy number	UK Biobank	395,718	European	35023831
AD: Alzheimer's disease	PGC	71,880/383,378	European	30617256
ADHD: Attention-deficit/hyperactivity disorder	PGC	20,183/35,191	European	29325848
AN: Anorexia nervosa	PGC	3,495/10,982	European	28494655
ASD: Autism spectrum disorder	PGC	18,381/27,969	European	30804558
BD: Bipolar disorder	PGC	41,917/371,549	European	34002096
MDD: Major depressive disorder	PGC	59,851/113,154	European	29700475
OCD: Obsessive compulsive disorder	PGC	2,688/7,037	European	28761083
SCZ: Schizophrenia	PGC	52,017/75,889	European	35396580
Anxiety disorders	FinnGen	44,663/301,879	European	https://storage.googleapis.com/finngen-public-dat
				a-r10/summary_stats/finngen_R10_KRA_PSY_A
				NXIETY_EXMORE.gz
PTSD:	FinnGen	2,615/368,054	European	https://storage.googleapis.com/finngen-public-dat
Post-traumatic stress disorder				a-r10/summary_stats/finngen_R10_F5_PTSD.gz

Table 1. Characteristics	of the used genom	e-wide association	study in the study

PGC, Psychiatric Genomics Consortium.

E	0.4	NI C			т		р	P*		Р		
Exposure	Outcome	No. of	Methods	OR	Lower	Upper	Р	P*	Cochran's Q	P	MR-Egger	Outliers from
		SNPs			95% CI	95% CI			test (I <sup>2</sup> )		intercept (P	MR-PRESSO
											value)	
mtDNA-CN	AD	54	IVW	0.971	0.940	1.004	0.088	0.438	59.968	0.238	0.400	rs1065853
			MR-Egger	1.002	0.926	1.083	0.968		-			
			WM	1.004	0.955	1.054	0.888					
mtDNA-CN	ADHD	51	IVW	0.960	0.776	1.187	0.705	1.000	61.105	0.135	0.946	NA
			MR-Egger	0.975	0.589	1.615	0.922					
			WM	0.945	0.700	1.275	0.710					
mtDNA-CN	AN	56	IVW	1.353	0.907	2.019	0.139	0.462	53.013	0.551	0.594	NA
			MR-Egger	1.070	0.415	2.760	0.890					
			WM	1.001	0.533	1.882	0.996					
mtDNA-CN	ASD	56	IVW	0.735	0.597	0.905	0.004	0.038	66.714	0.134	0.563	NA
			MR-Egger	0.836	0.516	1.355	0.470					
			WM	0.735	0.550	0.982	0.037					
mtDNA-CN	BD	53	IVW	1.088	0.921	1.286	0.321	0.642	85.458	0.002	0.422	NA
			MR-Egger	1.260	0.851	1.866	0.253					
			WM	1.100	0.894	1.354	0.369		1			
mtDNA-CN	MDD	53	IVW	1.035	0.904	1.185	0.617	1.000	75.320	0.019	0.608	NA
			MR-Egger	1.115	0.815	1.526	0.499					l
			WM	1.099	0.919	1.314	0.300					
mtDNA-CN	OCD	53	IVW	0.997	0.617	1.612	0.990	0.990	37.926	0.928	0.485	NA
			MR-Egger	0.691	0.224	2.135	0.524					
			WM	0.872	0.416	1.827	0.717		1			
mtDNA-CN	SCZ	53	IVW	1.015	0.846	1.218	0.871	1.000	119.179	<	0.484	NA
			MR-Egger	0.882	0.572	1.359	0.571		1	0.001		
			WM	0.964	0.789	1.177	0.717		1			

Table 2. Mendelian randomization estimates between genetically predicted mtDNA copy number and the risk of neuropsychiatric disorders.

mtDNA-CN	Anxiety	53	IVW	1.008	0.895	1.135	0.896	0.995	62.448	0.152	0.484	NA
	disorders		MR-Egger	0.923	0.703	1.212	0.567					
			WM	1.011	0.861	1.187	0.892					
mtDNA-CN	PTSD	53	IVW	1.345	0.901	2.008	0.147	0.368	40.390	0.879	0.696	NA
			MR-Egger	1.138	0.452	2.868	0.785					
			WM	1.369	0.753	2.488	0.303					

mtDNA-CN: mitochondrial DNA copy number; AD: Alzheimer's disease; ADHD: Attention-deficit/hyperactivity disorder; AN: Anorexia nervosa; ASD: Autism spectrum disorder; BD: Bipolar disorder; MDD: Major depressive disorder; OCD: Obsessive compulsive disorder; SCZ:Schizophrenia; PTSD: Post-traumatic stress disorder; SNPs single nucleotide polymorphisms.

The random-effects inverse variance-weighted (IVW) method was used as the primary approach, while other methods including MR-Egger, weighted median (WM) methods.Odds ratios (OR) for associations between genetically predicted mtDNA copy number and mental disorders. P\* represents the P adjusted by False discovery rate (FDR). Cochran's Q-test is used for heterogeneity testing, and a P < 0.05 is considered significant. MR-PRESSO analysis is used to identify and correct potential level pleiotropy outliers. MR-Egger intercept analysis was used to evaluate level pleiotropy, and P value < 0.05 was considered significant.

						• •		1 2			1,2		
Exposure Outcome	Outcome	No. of	Methods	beta	SE	Lower	Upper	Р	P*	Cochran's	Р	MR-Egger	Outliers from
	SNPs				95% CI	95%			Q test (I2)		intercept (P	MR-PRESSO	
						CI					value)		
AD	mtDNA-CN	22	IVW	-0.029	0.029	-0.087	0.029	0.325	0.814	35.996	0.022	0.848	rs41290120
			MR-Egger	-0.037	0.050	-0.135	0.062	0.474					
			WM	-0.011	0.032	-0.075	0.052	0.730					
ADHD	mtDNA-CN	11	IVW	0.003	0.010	-0.017	0.024	0.748	0.831	14.926	0.135	0.949	NA
			MR-Egger	0.007	0.051	-0.093	0.106	0.900					
			WM	0.008	0.012	-0.015	0.031	0.502					
AN	mtDNA-CN	4	IVW	-0.002	0.007	-0.015	0.011	0.757	0.757	1.051	0.789	0.508	NA
			MR-Egger	-0.018	0.021	-0.058	0.023	0.482					
			WM	-0.003	0.008	-0.019	0.012	0.684					
ASD	mtDNA-CN	14	IVW	0.007	0.008	-0.008	0.023	0.362	0.724	12.195	0.512	0.340	NA
			MR-Egger	0.032	0.026	-0.019	0.084	0.245					
			WM	0.001	0.011	-0.020	0.022	0.960					
BD	mtDNA-CN	43	IVW	0.003	0.006	-0.009	0.016	0.613	0.766	58.538	0.046	0.670	rs41315395
			MR-Egger	-0.013	0.038	-0.088	0.062	0.737					
			WM	0.005	0.008	-0.010	0.020	0.520					
MDD	mtDNA-CN	17	IVW	-0.006	0.012	-0.030	0.017	0.598	0.854	27.340	0.038	0.590	NA
			MR-Egger	0.002	0.020	-0.037	0.041	0.911					
			WM	-0.002	0.014	-0.029	0.026	0.911					
OCD	mtDNA-CN	2	IVW	-0.013	0.010	-0.033	0.007	0.209	1.000	2.452	0.117	-	-
			MR-Egger										
			WM										
SCZ	mtDNA-CN	129	IVW	0.003	0.004	-0.004	0.010	0.452	0.753	162.225	0.022	0.072	rs34555420
			MR-Egger	0.026	0.014	0.000	0.053	0.054					
			WM	0.004	0.005	-0.006	0.013	0.454					

Table 3. Reverse mendelian randomization estimates on associations of genetically predicted neuropsychiatric disorders and mtDNA copy number.

Anxiety	mtDNA-CN	39	IVW	0.029	0.010	0.010	0.048	0.003	0.030	46.918	0.152	0.798	rs4955420、
disorders			MR-Egger	0.038	0.038	-0.036	0.112	0.318					rs6123193
			WM	0.024	0.013	-0.001	0.050	0.062					
PTSD	mtDNA-CN	2	IVW	-0.019	0.018	-0.055	0.016	0.286	0.955	3.190	0.074	-	-
			MR-Egger										
			WM										

mtDNA-CN: mitochondrial DNA copy number; AD: Alzheimer's disease; ADHD: Attention-deficit/hyperactivity disorder; AN: Anorexia nervosa; ASD: Autism spectrum disorder; BD: Bipolar disorder; MDD: Major depressive disorder; OCD: Obsessive compulsive disorder; SCZ:Schizophrenia; PTSD: Post-traumatic stress disorder; SNPs single nucleotide polymorphisms; SE, standard error.

The random-effects inverse variance-weighted (IVW) method was used as the primary approach, while other methods including MR-Egger, weighted median (WM) methods.Odds ratios (OR) for associations between genetically predicted mtDNA copy number and mental disorders. P\* represents the P adjusted by False discovery rate (FDR). Cochran's Q-test is used for heterogeneity testing, and a P < 0.05 is considered significant. MR-PRESSO analysis is used to identify and correct potential level pleiotropy outliers. MR-Egger intercept analysis was used to evaluate level pleiotropy, and P value < 0.05 was considered significant.




Figure 1 The flowchart of bidirectional Mendelian randomization study explores the causal relationship between mitochondrial DNA copy number and neuropsychiatric disorders.

AD: Alzheimer's disease; ADHD: Attention-deficit/hyperactivity disorder; AN: Anorexia nervosa; ASD: Autism spectrum disorder; BD: Bipolar disorder; MDD: Major depressive disorder; OCD: Obsessive compulsive disorder; SCZ:Schizophrenia; PTSD: Post-traumatic stress disorder.

